dTBP-3

dTBP-3 inhibits hepatocellular carcinoma by blocking the TIGIT/PVR pathway to enhance tumor immunity, increase the proportions of NK cells and T cells, slow tumor growth, and prolong the survival of tumor-bearing mice^[1].
dTBP-3 (40 mg/kg, administered via tail vein base injection once every 3 days for a total of 5 doses) can enhance the in vivo anti-tumor effect against anti-PD-1-resistant triple-negative breast cancer via the PR-T@PLLD nanoplatform, strengthen the activity of CD8⁺ cytotoxic T cells, remodel the tumor immune microenvironment, and promote the secretion of pro-inflammatory cytokines; it can also induce the formation of immune memory in the body and effectively inhibit lung metastasis of triple-negative breast cancer^[2].
dTBP-3 can be used to synthesize the intravenous tracer [¹⁸F]TTDP. This probe specifically targets TIGIT-positive tumor-infiltrating lymphocytes in mice and humans, shows significantly higher tumor uptake than all control groups, can quantitatively reflect the intratumoral TIGIT expression level, predict the intervention effect of combined immunotherapy, and shares the same urinary metabolic clearance pathway in rhesus monkeys as in mice^[3].